BVT Knock-Out GNMSF/ DE000VE93FP5 /
9/24/2024 10:30:48 AM | Chg.+0.030 | Bid10:42:27 AM | Ask10:42:27 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
4.220EUR | +0.72% | - Bid Size: - |
- Ask Size: - |
Genmab A/S | 1,301.13 - | 12/31/2078 | Call |
GlobeNewswire
8/19
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults wit...
GlobeNewswire
6/28
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Re...
GlobeNewswire
4/30
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
4/3
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire
10/17/2023
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire
9/25/2023
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...
GlobeNewswire
9/4/2023
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...
GlobeNewswire
10/19/2021
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021